Head of Comparative Pathology

Join 2seventy’s enthusiastic and collaborative Preclinical Development team and contribute to the overall success of our novel immunotherapy and gene editing approaches. This role is in the department of Preclinical and Translational Development. The functions of this role will include the design and evaluation of target discovery and in vivo efficacy studies and work with our clinical and regulatory teams to generate the pharmacology, toxicology and biodistribution data that is critical to translating each of bluebird’s innovative therapies safely from research into patients.

In this role you will join our new Oncology spinoff, 2seventy bio, where we are excited to continue leading the charge on Oncology cell therapy research.   We’ll combine our real-world clinical data from our approved multiple myeloma treatment with our tool kit of several cutting-edge technologies, dedicated partners, passionate innovators that care, and our unwavering dedication to important life-changing work.  We strive to make a difference and offer more time for patients with cancer.  We show up daily for our patients (literally and figuratively) and we feel privileged to be a part of their journey.  If you want to challenge the status quo while having fun doing so, come be a part of this unique and exciting opportunity - we can’t wait to talk to you! 

As a Director/ Senior Director reporting to the Head of Preclinical and Translational Development, you'll:

• Assess new targets and products for mechanism(s) of toxicity to determine clinical relevance and ways to minimize clinical impact and/or effectively position bluebird products.
• Design and evaluate in situ hybridization, immunohistochemistry and immunofluorescence studies in support of target discovery efforts.
• Evaluate the clinical symptoms, clinical pathology, gross and microscopic tissue changes and changes in protein and/or mRNA expression associated with immunotherapies or gene-edited stem cell therapies.
• Utilize digital imaging and image analysis to provide additional objective endpoints for in vivo studies.
• Serve as nonclinical strategy lead for cell therapy oncology programs and as lead for the design, implementation and reporting of preclinical in vitro and in vivo immunopharmacology and/or toxicology (safety) studies to support bbb clinical development programs.
• Opportunity to lead a state of the art histology laboratory with routine H&E capability along with molecular pathology (ISH, IHC, IF, multiplex), human tissue bank
• Work cross-functionally across the organization to ensure effective execution on nonclinical program deliverables, including with Research, CMC, Regulatory, and Clinical functions.
• Study results interpretation, report preparation, and support the preparation of integrated nonclinical summaries for IND/CTA filings.
• Be able to incorporate data into comprehensive study reports and regulatory documents 

You’re who we’re looking for if you:

• DVM degree (or equivalent) with specialty training in veterinary pathology in the form of a pathology residency
• ACVP/ECVP board certification is preferred
• PhD in biological science, ideally in immunology, oncology, pharmacology, or toxicology
• Ideally 2 to 5 years industry experience with expertise in in vivo study design and execution
• Experience in the nonclinical development of biotherapeutics, cell therapies, gene therapies, and gene edited products is desirable.
• Background and/or demonstrated skills in the practical application of investigative safety.
• Familiarity with regulatory guidelines to support clinical development and registrational filings would be an advantage.
• Experience managing a team of technicians
• Comfortable working with cross-functional immunotherapy and gene therapy research teams
• Experience with or willingness to learn how to supervise, train and develop junior staff
• Be ready to embrace the principles of the bluebird bio culture: b colorful, b cooperative, and b yourself